[Form 4] AAR Corp. Insider Trading Activity

Rhea-AI Filing Summary

Vir Biotechnology (VIR) Form 4 filing: Director Vicki L. Sato sold 22,000 common shares on 08/01/2025 pursuant to a Rule 10b5-1 plan adopted 03/27/2025.

The weighted-average sale price was $4.9863 (transaction range $4.89–$5.04), implying gross proceeds of roughly $0.11 million. After the sale, Sato directly owns 1,276,391 shares, a reduction of about 1.7% of her prior stake.

No derivative securities were reported. The single, pre-planned sale suggests limited insider profit-taking rather than a material change in ownership or company outlook.

Positive

• None.

Negative

• Director insider sale: 22,000 shares sold, which can be viewed as a slight negative sentiment indicator, although size is relatively small.

Insights

Securities Analyst

TL;DR: Small, pre-planned insider sale; negligible ownership impact; mildly negative sentiment signal but limited financial relevance.

The 22 k-share sale equals <1% of average daily volume and only trims the director’s stake by ~1.7%, leaving a sizeable 1.28 m-share holding. Because the trade was executed under a Rule 10b5-1 plan, it carries less informational value than discretionary selling. Insider activity is modestly negative from a sentiment standpoint, yet the minimal size and continued large holding mitigate concern. No operational or financial metrics are disclosed, so the filing is not materially impactful to VIR’s valuation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garascia Jessica A.

(Last) (First) (Middle)

1100 N. WOOD DALE ROAD

(Street)

WOOD DALE IL 60191

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AAR CORP [ AIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior VP, GC, CAO & Secretary

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/31/2025		F(1)		881	D	$74.71	38,236	D
Common Stock	07/31/2025		F(2)		3,892	D	$74.71	34,344	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is reporting the withholding of 881 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of time-based restricted stock.

2. The reporting person is reporting the withholding of 3,892 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of performance-based stock.

	/s/ Katherine Kwiat, power of attorney	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Vir Biotechnology (VIR) shares did the director sell?

Director Vicki L. Sato sold 22,000 shares of VIR common stock.

What price did the insider receive for Vir Biotechnology shares?

The weighted-average sale price was $4.9863, with individual trades between $4.89 and $5.04.

How much stock does the director still own after the sale?

Following the transaction, Sato owns 1,276,391 VIR shares directly.

Was the VIR insider sale part of a 10b5-1 trading plan?

Yes. The sale was executed under a Rule 10b5-1 plan adopted on March 27, 2025.

Does this Form 4 include derivative security transactions?

No. No derivative securities were reported in this filing.